Pharmaceutical combination having potent antiviral activity against single-stranded RNA viruses
AssigneeFeynman Labs, LLC
InventorsCarl Johan Freer, Richard Kaszynski, Alessandro Gadotti
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for treating viral infections, including treatments for treatments for coronavirus infections, such as SARS-CoV-2 infections, and illnesses due to the viral infections, such as COVID-19 is provided herein. Also provided are methods for treating viral infections as well as illnesses due to viral infections, such as COVID-19.
Claims12
A combination comprising an antiviral agent and an antiparasitic agent, wherein the antiviral agent inhibits RNA-dependent RNA polymerase and the antiparasitic agent is an avermectin, wherein the antiviral agent is favipiravir in a dose selected from the group consisting of between about 1600 mg and about 1800 mg or between about 600 mg and about 800 mg;
- and wherein the avermectin is ivermectin in a dose of about 150 μg/kg.
A method for treating a microbial infection comprising administering to a subject in need thereof a combination of an antiviral agent and an antiparasitic agent, wherein the antiviral agent inhibits RNA-dependent RNA polymerase and the antiparasitic agent is an avermectin, wherein the antiviral agent is favipiravir administered in a dose selected from the group consisting of between about 1600 mg and about 1800 mg or between about 600 mg and about 800 mg;
- and wherein the avermectin is ivermectin administered in a dose of about 150 μg/kg.
Dependencies are inferred from the claim text.